LINC00165

Across TCGA pan-cancer cohorts, LINC00165 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of LINC00165’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where LINC00165 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC00165 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, HNSC, and THCA are the cancer types where LINC00165 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC00165 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.960	<.001	9	view →
HNSC	All	All	+0.814	<.001	8	view →
THCA	Male	All	+0.221	<.001	7	view →
KIRC	All	All	+0.176	<.001	7	view →
LUSC	Female	II,III,IV	−1.351	<.001	6	view →
BRCA	All	III,IV	−0.817	<.001	6	view →
UCEC	All	IV	−0.220	.002	2	view →
KICH	Female	II,III,IV	+0.067	.031	1	view →
LIHC	Male	All	+0.012	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

LINC00165–LUAD

Open the LUAD breakdown →